Supplement 4: Treatment network for a) all studies, b) those with active tuberculosis data, and c) those with hepatotoxicity data*

a) All studies

No treatment → INH 3-4m → INH 6m → INH 9m → INH 12-72m → INH - EMB → RFB -INH → RFB -INH high → RPT -INH → Placebo → RMP → RMP - INH 1m → RMP - INH 3-4m

b) Active TB

No treatment → INH 3-4m → INH 6m → INH 9m → INH 12-72m → INH - EMB → RFB -INH → RFB -INH high → RPT -INH → Placebo → RMP → RMP - INH 1m → RMP - INH 3-4m

c) Hepatotoxicity

No treatment → INH 3-4m → INH 6m → INH 9m → INH 12-72m → INH - EMB → RFB -INH → RFB -INH high → RPT -INH → Placebo → RMP → RMP - PZA → RMP - INH -PZA → Placebo → RMP
Unlabelled connections indicate one study reporting that treatment pair; for two or more studies lines are proportionally thicker, and labelled with the number of studies. Colour coding indicates classes of treatment. Dotted boxes indicate a lack of data. RFB-INH: 300mg RFB plus 750mg INH twice weekly for 3 months, RFB-INH high: 600mg RFB plus 750mg INH twice weekly for 3 months. 4m-four months, etc., EMB- ethambutol; INH-isoniazid, PZA-pyrazinamide, RFB-rifabutin, RMP-rifampicin, RPT-rifapentine, TB-tuberculosis